Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824001484 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162595994009600 |
|---|---|
| author | E. Burton V. Honaker D. Milton I. Glitza R. Amaria S. Patel A. Diab M. Wong J. McQuade C. Chung J. Wefel J. Li M. Davies H. Tawbi |
| author_facet | E. Burton V. Honaker D. Milton I. Glitza R. Amaria S. Patel A. Diab M. Wong J. McQuade C. Chung J. Wefel J. Li M. Davies H. Tawbi |
| author_sort | E. Burton |
| collection | DOAJ |
| format | Article |
| id | doaj-art-30eceabcfd0544f58319554573e99216 |
| institution | OA Journals |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-30eceabcfd0544f58319554573e992162025-08-20T02:22:32ZengElsevierEJC Skin Cancer2772-61182024-01-01210016010.1016/j.ejcskn.2024.100160Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)E. Burton0V. Honaker1D. Milton2I. Glitza3R. Amaria4S. Patel5A. Diab6M. Wong7J. McQuade8C. Chung9J. Wefel10J. Li11M. Davies12H. Tawbi13University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of AmericaUniversity of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of Americahttp://www.sciencedirect.com/science/article/pii/S2772611824001484 |
| spellingShingle | E. Burton V. Honaker D. Milton I. Glitza R. Amaria S. Patel A. Diab M. Wong J. McQuade C. Chung J. Wefel J. Li M. Davies H. Tawbi Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) EJC Skin Cancer |
| title | Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
| title_full | Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
| title_fullStr | Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
| title_full_unstemmed | Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
| title_short | Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
| title_sort | phase 2 study of atezolizumab bevacizumab and cobinetinib taco in patients pts with pd1 refractory metastatic brain metastases mbm |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824001484 |
| work_keys_str_mv | AT eburton phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT vhonaker phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT dmilton phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT iglitza phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT ramaria phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT spatel phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT adiab phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT mwong phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT jmcquade phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT cchung phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT jwefel phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT jli phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT mdavies phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm AT htawbi phase2studyofatezolizumabbevacizumabandcobinetinibtacoinpatientsptswithpd1refractorymetastaticbrainmetastasesmbm |